The financing is supported by subscription and underwriting commitments corresponding to approximately 70 percent of the contemplated transaction.
The financing is structured in three stages. The initial rights issue is accompanied by warrants of two separate series. Both warrant series are expected to be exercisable during 2026. Assuming full subscription of the initial rights issue and full exercise of both warrant series, the Company may receive aggregate gross proceeds of more than SEK 106 million before transaction costs.
The purpose of the financing is to support the Company's continued Medicare reimbursement approval process and commercialization activities in the United States and Europe, as well as general corporate purposes.
The transaction is being conducted in Sweden in accordance with applicable Swedish law and is directed solely to persons who may lawfully participate under applicable laws and regulations. No securities are being offered to the public in the United States.
This press release is provided for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or in any other jurisdiction where such offer or solicitation would be unlawful. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements thereof.
For more information, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01
Email: fredrik.rickman@prostatypegenomics.com
Prostatype® is a genetic test intended to support treatment decision-making for patients diagnosed with prostate cancer. The test was developed by a research group at Karolinska Institutet and is commercialized by Prostatype Genomics AB.